Trial · NCT02183688
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
NCT02183688, Phase 3, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients. Trials, record NCT02183688. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02183688
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
- NCT number
- NCT02183688
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,889 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Migraine Disorders
- Interventions
- Low dose ASA, High dose ASA, Low dose paracetamol, High dose paracetamol, Caffeine, Placebo
- First posted
- 2014-07-08
- Last updated
- 2014-07-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Calculated time to 50% pain relief, based on the pain intensity evaluated on a visual analogue scale (VAS) | 30 min., 1, 2, 3 and 4 hours after administration of the study medication | |
| Secondary | Percentage of patients with 50 % pain relief, evaluated on a VAS | At least 2 hours after administration of the study medication | |
| Secondary | Percentage of patients with 50 % pain relief, evaluated on a VAS | At least 30 min., 1, 3, and 4 hours after administration of the study medication | |
| Secondary | Pain intensity, evaluated on a VAS | 30 min., 1, 2, 3 and 4 hours after administration of the study medication | |
| Secondary | Ratio of weighted sum of pain intensity difference scores to maximum achievable sum of pain intensity differences (%SPIDweighted), evaluated on a VAS | Up to the end of the study | |
| Secondary | Extent of impairment of daily activities, evaluated on a 4-grade verbal scale (VRS) | Before, 30 min., 1, 2, 3 and 4 hours after administration of study drug | |
| Secondary | Duration of headache | Up to 48 hours after onset of each headache episode | |
| Secondary | Global assessment of efficacy by the patient, evaluated on a 4-grade VRS | Within 12 hours after study drug administration | |
| Secondary | Global assessment of tolerability by the patient, evaluated on a 4-grade VRS | Within 12 hours after study drug administration | |
| Secondary | Number of patients with adverse events | Up to the end of the study |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02183688
GET https://conductscience.org/api/trials/v1/NCT02183688/registered